tetano
Editor, Senior Moderator
Chemotherapy
. 2021 Mar 23;1-9.
doi: 10.1159/000515344. Online ahead of print.
Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection
Ornella Spagnolello[SUP] 1 [/SUP], Claudia Pinacchio[SUP] 1 [/SUP], Letizia Santinelli[SUP] 1 [/SUP], Paolo Vassalini[SUP] 1 [/SUP], Giuseppe Pietro Innocenti[SUP] 1 [/SUP], Gabriella De Girolamo[SUP] 1 2 [/SUP], Silvia Fabris[SUP] 3 [/SUP], Marta Giovanetti[SUP] 3 4 5 [/SUP], Silvia Angeletti[SUP] 6 [/SUP], Alessandro Russo[SUP] 1 2 [/SUP], Claudio M Mastroianni[SUP] 1 2 [/SUP], Massimo Ciccozzi[SUP] 3 [/SUP], Giancarlo Ceccarelli[SUP] 7 8 9 [/SUP], Gabriella d'Ettorre[SUP] 1 2 [/SUP]
Affiliations
Abstract
Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.
Keywords: COVID-19; Dysbiosis; Gut-lung axis; Probiotics; Systemic cytokine storm.
. 2021 Mar 23;1-9.
doi: 10.1159/000515344. Online ahead of print.
Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection
Ornella Spagnolello[SUP] 1 [/SUP], Claudia Pinacchio[SUP] 1 [/SUP], Letizia Santinelli[SUP] 1 [/SUP], Paolo Vassalini[SUP] 1 [/SUP], Giuseppe Pietro Innocenti[SUP] 1 [/SUP], Gabriella De Girolamo[SUP] 1 2 [/SUP], Silvia Fabris[SUP] 3 [/SUP], Marta Giovanetti[SUP] 3 4 5 [/SUP], Silvia Angeletti[SUP] 6 [/SUP], Alessandro Russo[SUP] 1 2 [/SUP], Claudio M Mastroianni[SUP] 1 2 [/SUP], Massimo Ciccozzi[SUP] 3 [/SUP], Giancarlo Ceccarelli[SUP] 7 8 9 [/SUP], Gabriella d'Ettorre[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33756475
- DOI: 10.1159/000515344
Abstract
Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia.
Keywords: COVID-19; Dysbiosis; Gut-lung axis; Probiotics; Systemic cytokine storm.